TargetMol

Tosedostat

Product Code:
 
TAR-T6301
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6301-1mg1mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-2mg2mg£123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-1mL1 mL * 10 mM (in DMSO)£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-5mg5mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-10mg10mg£244.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-25mg25mg£425.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-50mg50mg£592.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6301-100mg100mg£814.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CHR-2797 is an orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid deprivation, inhibition of protein synthesis due to a decrease in the intracellular free amino acid pool, an increase in the level of the proapoptotic protein Noxa, and cell death.
CAS:
238750-77-1
Formula:
C21H30N2O6
Molecular Weight:
406.479
Pathway:
Neuroscience; Metabolism
Purity:
0.98
SMILES:
CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1
Target:
Aminopeptidase; AChR

References

Krige D,etal.CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.Cancer Res. 2008 Aug 15;68(16):6669-79. Smith EM, et al.The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway.Oncotarget. 2015 Jul 10;6(19):17314-27. Jenkins C, et al. Leuk Res. 2011 May;35(5):677-81. van Herpen CM, et al. Br J Cancer. 2010 Oct 26;103(9):1362-8.